H-FABP, Human, mAb 66E2

Catalog #: HM2016
Quantity: 100 µg

Original supplier of innate immunity products since 1994.

Our commitment to quality: Read more!

Contact our support team for more product information.

Can't find your application for a product? Request a sample!

The monoclonal antibody 66E2 recognizes human heart fatty acid binding protein (H-FABP) of both natural and recombinant origing. The H-FABP protein is derived from the human FABP3 gene. FABPs are small intracellular proteins (~13-14 kDa) with a high degree of tissue specificity that bind long chain fatty acids. They are abundantly present in various cell types and play an important role in the intracellular utilization of fatty acids, transport and metabolism. There are at least nine distinct types of FABP, each showing a specific pattern of tissue expression. Due to its small size, FABP leaks rapidly out of ischemically damaged necrotic cells leading to a rise in serum levels. Ischemically damaged tissues are characterized histologically by absence (or low presence) of FABP facilitating recognition of such areas. H-FABP is localized in the heart, skeletal and smooth muscle, mammary epithelial cells, aorta, distal tubules of the kidney, lung, brain, placenta, and ovary. The monoclonal antibody 66E2 stains heart muscle cells and striated skeletal muscle cells in immunohistology. It can be used to detect ischemia areas of human heart. It is also useful as marker for brain damage. Furthermore, this antibody is useful for the purification of H-FABP.


Catalog number HM2016
Product type Monoclonal antibodies
Quantity 100 µg
Formulation 1 ml (100 μg/ml) 0.2 μm protein G purified antibody solution in PBS, containing 0.1% bovine serum albumin and 0.02% sodium azide.
Immunogen Purified human H-FABP
Isotype Mouse IgG1
Species Human
Cross reactivity Mouse - Yes, Rat - Yes, Swine - Yes
Alias Heart-type fatty acid-binding protein, Fatty acid-binding protein 3, FABP3, Muscle fatty acid-binding protein, Mammary-derived growth inhibitor
Gene name: FABP3, FABP11, MDGI
Storage and stability Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
Precautions For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use or derivation of this product.
Disease Cardiology and metabolism, Neurological disorders
  • Application:
    F, IA, IP, W
  • Application Notes:
    IP: Biotinylated 66E2 was immobilized on streptavidin beads and added to serum to immunoprecipitate H-FABP (Ref.5).
    W: Reduced sample treatment. The band size is ~15 kDa (Ref.4). 1μg/ml was used (Ref.6).
    F: Permeabilization was done in cold acetone with 0.5% hydrogen peroxidase for 10 min, after drying and washing, antibodies were incubated for 30 minutes.
  • Positive Control:
    Heart cells or recombinant H-FABP
  • Negative Control:
    Tonsil tissue
  • Use:
    Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.
1. Roos, W et al; Monoclonal antibodies to human heart fatty acid-binding protein. J Immunol Meth 1995, 183: 149
2. Guillaume, E et al; A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2003, 3: 1495
3. Zimmermann-Ivol, C et al; Fatty acid binding protein as a serum marker for the early diagnosis of stroke. Mol Cell Proteomics 2004, 3: 66
4. Pelsers, M et al; Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. Clin Chem 2004, 50: 1568
5. Zhen, E et al; Quantification of heart fatty acid binding protein as a biomarker for drug-induced cardiac and musculoskeletal necroses. Proteomics Clin Appl 2007, 1: 661
6. Tolle, A et al; Fatty acid binding proteins (FABPs) in prostate, bladder and kidney cancer cell lines and the use of IL-FABP as survival predictor in patients with renal cell carcinoma. BMC Cancer 2011, 11:302
You may also be interested in the following product(s)
Product description
Catalog #